Is Regeneron a Multimillionaire-Maker Stock?
(NASDAQ: REGN) has encountered several headwinds over the past two years, including the loss of patent exclusivity for one of its growth drivers, Eylea, a medicine for wet age-related macular degeneration. Even as its long-term returns remain solid, the stock has not performed particularly well over the last 24 months. There are several reasons why Regeneron could bounce back -- in fact, it has already begun to do so, with its shares up 35% over the past six months.
But does the biotech have what it takes to crush the market over the long run and turn average investors into multimillionaires?
Image source: Getty Images.
Source Fool.com
Regeneron Pharmaceuticals Inc. Aktie
662,70 €
-0,26 %
Regeneron Pharmaceuticals Inc. wird von der Community favorisiert: Deutlich mehr Buy- als Sell-Einschätzungen.
Für Regeneron Pharmaceuticals Inc. ergibt sich ein leicht positives Potenzial, angesichts eines Kursziels von 710 € im Vergleich zu 662.7 €.
